{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:15:35Z","timestamp":1790201735519,"version":"4.1.0"},"reference-count":24,"publisher":"BMJ","issue":"6","funder":[{"name":"CMV Action"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Congenital cytomegalovirus (cCMV) is the most common infectious cause of congenital disability. It can disrupt neurodevelopment, causing lifelong impairments including sensorineural hearing loss and developmental delay. This study aimed, for the first time, to estimate the annual economic burden of managing cCMV and its sequelae in the UK.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>The study collated available secondary data to develop a static cost model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting<\/jats:title><jats:p>The model aimed to estimate costs of cCMV in the UK for the year 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Individuals of all ages with cCMV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main outcome measures<\/jats:title><jats:p>Direct (incurred by the public sector) and indirect (incurred personally or by society) costs associated with management of cCMV and its sequelae.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The model estimated that the total cost of cCMV to the UK in 2016 was \u00a3732\u2009million (lower and upper estimates were between \u00a3495 and \u00a3942\u2009million). Approximately 40% of the costs were directly incurred by the public sector, with the remaining 60% being indirect costs, including lost productivity. Long-term impairments caused by the virus had a higher financial burden than the acute management of cCMV.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The cost of cCMV is substantial, predominantly stemming from long-term impairments. Costs should be compared against investment in educational strategies and vaccine development programmes that aim to prevent virus transmission, as well as the value of introducing universal screening for cCMV to both increase detection of children who would benefit from treatment, and to build a more robust evidence base for future research.<\/jats:p><\/jats:sec>","DOI":"10.1136\/archdischild-2018-316010","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T04:32:53Z","timestamp":1543206773000},"page":"559-563","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":61,"title":["Economic cost of congenital CMV in the UK"],"prefix":"10.1136","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0008-3104","authenticated-orcid":false,"given":"Jenny","family":"Retzler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Hex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Star","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,11,24]]},"reference":[{"key":"2021102500301564000_104.6.559.1","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.655"},{"key":"2021102500301564000_104.6.559.2","doi-asserted-by":"crossref","unstructured":"Pembrey L , Raynor P , Griffiths P , et al . Seroprevalence of cytomegalovirus, Epstein Barr virus and varicella zoster virus among pregnant women in Bradford: a cohort study. PLoS One 2013;8:e81881.doi:10.1371\/journal.pone.0081881","DOI":"10.1371\/journal.pone.0081881"},{"key":"2021102500301564000_104.6.559.3","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2015-309656"},{"key":"2021102500301564000_104.6.559.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30143-3"},{"key":"2021102500301564000_104.6.559.5","first-page":"33","article-title":"Congenital cytomegalovirus infection, knowledge and attitudes among maternal health professionals and pregnant women","volume":"27","author":"Wood","year":"2017","journal-title":"Midirs Midwifery Digest"},{"key":"2021102500301564000_104.6.559.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2012.06.022"},{"key":"2021102500301564000_104.6.559.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/IDOG\/2006\/80383","article-title":"Knowledge and awareness of congenital cytomegalovirus among women","volume":"2006","author":"Jeon","year":"2006","journal-title":"Infect Dis Obstet Gynecol"},{"key":"2021102500301564000_104.6.559.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1404599"},{"key":"2021102500301564000_104.6.559.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2009.08.012"},{"key":"2021102500301564000_104.6.559.10","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/dmcn.13556","article-title":"Long-term impairment attributable to congenital cytomegalovirus infection: a retrospective cohort study","volume":"59","author":"Korndewal","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"2021102500301564000_104.6.559.11","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamapediatrics.2016.2016","article-title":"Cost-effectiveness of Universal and targeted newborn screening for congenital cytomegalovirus infection","volume":"170","author":"Gantt","year":"2016","journal-title":"JAMA Pediatr"},{"key":"2021102500301564000_104.6.559.12","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2014-306756"},{"key":"2021102500301564000_104.6.559.13","unstructured":"Vaccines VBI , Releases P . VBI Vaccines announces positive final phase 1 study results of preventative CMV vaccine. 2018 https:\/\/www.vbivaccines.com\/wire\/cmv-vaccine-phase-1-study-results\/"},{"key":"2021102500301564000_104.6.559.14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2015-0908"},{"key":"2021102500301564000_104.6.559.15","doi-asserted-by":"crossref","unstructured":"Lanzieri TM , Chung W , Flores M , et al . Hearing loss in children with asymptomatic congenital cytomegalovirus infection. Pediatrics 2017;139:e20162610.doi:10.1542\/peds.2016-2610","DOI":"10.1542\/peds.2016-2610"},{"key":"2021102500301564000_104.6.559.16","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.130.5.524"},{"key":"2021102500301564000_104.6.559.17","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1007\/s00405-016-3941-5","article-title":"Bone-anchored hearing aids in conductive and mixed hearing losses: why do patients reject them?","volume":"273","author":"Siau","year":"2016","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"2021102500301564000_104.6.559.18","unstructured":"Department of Health. NHS reference costs. 2015\/16. https:\/\/www.gov.uk\/government\/publications\/nhs-reference-costs-2015-to-2016"},{"key":"2021102500301564000_104.6.559.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1991.tb13358.x"},{"key":"2021102500301564000_104.6.559.20","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-312805"},{"key":"2021102500301564000_104.6.559.21","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.535"},{"key":"2021102500301564000_104.6.559.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)92138-4"},{"key":"2021102500301564000_104.6.559.23","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.544"},{"key":"2021102500301564000_104.6.559.24","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2010.199901"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2018-316010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T03:34:38Z","timestamp":1635132878000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2018-316010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,24]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,5,17]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1136\/archdischild-2018-316010"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2018-316010","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,24]]}}}